THE FIRST DUAL-DRUG ADVANCED LIPOSOMAL FORMULATION1

A CLOSER LOOK AT VYXEOS: MECHANISM OF ACTION

OPTIMIZING THE DELIVERY OF DAUNORUBICIN AND CYTARABINE2

synergetic-ratio-desktop
Adapted from the VYXEOS Product Monograph.
synergetic-ratio-mobile
Adapted from the VYXEOS Product Monograph.

*As shown in animal models.

†As shown in vitro.

‡The advanced liposomal membrane is composed of distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG) and cholesterol in a 7:2:1 ratio.3

References: 1. Tolcher AW, Mayer LD. Improving combination cancer therapy: the CombiPlex® development platform. Future Oncol 2018;14:1317–1332. 2. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692. 3. Current VYXEOS® Product Monograph, Jazz Pharmaceuticals Canada, Inc.

CA-VYX-2400009-E | March 2024